1629869-44-8
基本信息
CS-2483
Pimodivir
VRT0928787
VRT-0928787
VRT 0928787
Pimodivir (VX-787)
VX-787 (Pimodivir)
VX-787
VX 787
VX787
JNJ-872
JNJ 872
JNJ872
VRT-0928787
VRT 0928787
VRT0928787
PIMODIVIR
(2S,3S)-3-[[5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
物理化学性质
| 密度 | 1.501±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | Soluble in DMSO, not in water:100.0(Max Conc. mg/mL);250.38(Max Conc. mM) |
| 酸度系数(pKa) | 4.32±0.40(Predicted) |
| 形态 | 固体 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
VX-787价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-12353A | VX-787 Pimodivir | 1629869-44-8 | 5mg | 900元 |
| 2024/04/30 | HY-12353A | VX-787 Pimodivir | 1629869-44-8 | 10mg | 1500元 |
| 2024/04/30 | HY-12353A | VX-787 Pimodivir | 1629869-44-8 | 50 mg | 5100元 |
常见问题列表
Pimodivir rescues macrophages from virus-mediated death at non-cytotoxic concentrations 24 hpi. The EC 50 value for Pimodivir are 8 and 12 nM for A(H1N1) and A(H3N2) strains, respectively, whereas the CC 50 values are >1 μM, giving selectivity indexes (SI) > 125 and > 83 for A(H1N1) and A(H3N2) strains, respectively. Pimodivir significantly attenuates the transcription of viral M1 RNA in macrophages, which are infected with A(H1N1) or A(H3N2) strains for 8 h. Pimodivir inhibits the transcription of viral but not cellular genes. Pimodivir allows some activation of IAV-mediated expression of several cellular genes, which are involved in tryptophan and nucleotide metabolism. Pimodivir possesses excellent anti-IAV but not immuno/metabolo-modulating effect. Pimodivir (VX-787) is very potent against influenza A strains, including pandemic 2009 H1N1 and avian H5N1. Pimodivir (VX-787) shows potent activity against all influenza A virus strains tested, with an EC 50 range of 0.13 to 3.2 nM. Pimodivir-selected PB2 variant viruses maintain susceptibility to neuraminidase inhibitors in vitro.
Pimodivir (2, 6, and 20 mg/kg/day, p.o.) and GS 4071 (20 mg/kg/day) completely prevent death in the H1N1pdm virus infection in mice. Pimodivir (20 mg/kg/day) is more effective than GS 4071 (20 mg/kg/day) in improving body weight and reducing the severity of lung infection. Moreover, Pimodivir (VX-787) shows 100% survival in a +48 h delay to treatment mouse influenza model at 10, 3 and 1 mpk (BID × 10 days) whereas the SOC, GS 4071, provide no survival benefit in this model at 10 mpk. Pimodivir (VX-787; 1, 3, or 10 mg/kg, bid) provided complete survival, with a dose-dependent reduction in BW loss of the mice.